Cytek Biosciences (CTKB) Asset Utilization Ratio (2021 - 2026)

Cytek Biosciences has reported Asset Utilization Ratio for 6 years, with the latest figure at 0.45 in Q1 2026.

• For the quarter ending Q1 2026, Asset Utilization Ratio rose 11.74% year-over-year to 0.45; the trailing twelve-month figure through Mar 2026 stood at 0.45 (up 11.74% YoY), and the FY2025 full-year result was 0.42, up 3.96% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.45, up from 0.42 in the prior quarter.
• The five-year high for Asset Utilization Ratio was 0.45 in Q1 2026, with the low at 0.03 in Q1 2022.
• Historically, Asset Utilization Ratio has averaged 0.33 across 5 years, with a median of 0.4 in 2025.
• The largest YoY upside for Asset Utilization Ratio was 6674.42% in 2022 against a maximum downside of 27.79% in 2022.
• Cytek Biosciences' Asset Utilization Ratio stood at 0.32 in 2022, then rose by 18.23% to 0.38 in 2023, then advanced by 6.28% to 0.4 in 2024, then grew by 4.12% to 0.42 in 2025, then increased by 6.43% to 0.45 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.45 (Q1 2026), 0.42 (Q4 2025), and 0.4 (Q3 2025), per Business Quant data.